SAXAGLIPTIN HYDROCHLORIDE
| Brand name | ONGLYZA |
|---|---|
| Active ingredient | SAXAGLIPTIN HYDROCHLORIDE |
| Strength | EQ 2.5MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** |
| Dosage form | TABLET |
| Route | ORAL |
| Modality | Small molecule |
| FDA approval | July 2009 |
| Marketing status | DISCN |
| Patent | Expires | Type |
|---|---|---|
| 7951400 | November 2028 | product |
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.